GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Preferred Stock

ENTA (Enanta Pharmaceuticals) Preferred Stock : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Enanta Pharmaceuticals's preferred stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Enanta Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was $-37.57 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Enanta Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 was $5.24.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Enanta Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-1.05.


Enanta Pharmaceuticals Preferred Stock Historical Data

The historical data trend for Enanta Pharmaceuticals's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Preferred Stock Chart

Enanta Pharmaceuticals Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enanta Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enanta Pharmaceuticals Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Enanta Pharmaceuticals  (NAS:ENTA) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Enanta Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Enanta Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Enanta Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the three months ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enanta Pharmaceuticals Preferred Stock Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Jay R. Luly director, officer: President and CEO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus officer: Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or officer: Chief Scientific Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett officer: Treasurer and CFO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Terry Vance director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901